Madrigal pharmaceuticals completes submission of new drug application seeking accelerated approval of resmetirom for the treatment of nash with liver fibrosis

Conshohocken, pa., july 17, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), announced the completion of the rolling submission of its new drug application (nda) to the u.s. food and drug administration (fda) for resmetirom for the treatment of adults with nash with liver fibrosis, a disease with no approved therapy. madrigal has requested a priority review of the resmetirom nda.
MDGL Ratings Summary
MDGL Quant Ranking